BUILDER v.2: Improving the chemistry of a de novo design strategy

SummarySignificant improvements have been made to the de novo drug design program BUILDER. The BUILDER strategy is to find molecule templates that bind tightly to ‘hot spots’ in the target receptor, and then generate bridges to join these templates. In this paper, the bridging algorithm has been further developed to improve the chemical sense and diversity of the bridges, as well as the robustness of the technique. The improved algorithm is then applied to rebuild known bridges in methotrexate and HIV protease. Finally, the entire BUILDER approach is tested by rebuilding methotrexate de novo.

[1]  Stephen L. Sacks,et al.  Synthesis and antiviral activity of 11-azapentacyclo[6.2.1.0.2,70.4,1005,9]decane , 1985 .

[2]  C. Levinthal,et al.  Predicting antibody hypervariable loop conformations II: Minimization and molecular dynamics studies of MCPC603 from many randomly generated loop conformations , 1986, Proteins.

[3]  M. Murcko,et al.  GroupBuild: a fragment-based method for de novo drug design. , 1993, Journal of medicinal chemistry.

[4]  C. Levinthal,et al.  Predicting antibody hypervariable loop conformation. I. Ensembles of random conformations for ringlike structures , 1987, Biopolymers.

[5]  I. Kuntz,et al.  Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Regine Bohacek,et al.  Multiple Highly Diverse Structures Complementary to Enzyme Binding Sites: Results of Extensive Application of a de Novo Design Method Incorporating Combinatorial Growth , 1994 .

[7]  M. Karplus,et al.  Functionality maps of binding sites: A multiple copy simultaneous search method , 1991, Proteins.

[8]  Andrew R. Leach,et al.  Automated molecular design: A new fragment-joining algorithm , 1994, J. Comput. Aided Mol. Des..

[9]  W. Ripka,et al.  Molecular modeling in the design of phospholipase A2 inhibitors , 1989, Journal of cellular biochemistry.

[10]  Mark A. Murcko,et al.  GenStar: A method for de novo drug design , 1993, J. Comput. Aided Mol. Des..

[11]  Richard A. Lewis.  Automated site-directed drug design: Approaches to the formation of 3D molecular graphs , 1990, J. Comput. Aided Mol. Des..

[12]  S. Freer,et al.  Design of enzyme inhibitors using iterative protein crystallographic analysis. , 1991, Journal of medicinal chemistry.

[13]  W. Howe,et al.  Computer design of bioactive molecules: A method for receptor‐based de novo ligand design , 1991, Proteins.

[14]  Chris M. W. Ho,et al.  SPLICE: A program to assemble partial query solutions from three-dimensional database searches into novel ligands , 1993, J. Comput. Aided Mol. Des..

[15]  J. Bolin,et al.  Crystal structures of Escherichia coli and Lactobacillus casei dihydrofolate reductase refined at 1.7 A resolution. I. General features and binding of methotrexate. , 1982, The Journal of biological chemistry.

[16]  J J Baldwin,et al.  Carbonic anhydrase inhibitors for the treatment of glaucoma , 2023, Медицинская этика.

[17]  Valerie J. Gillet,et al.  SPROUT: Recent developments in the de novo design of molecules , 1994, J. Chem. Inf. Comput. Sci..

[18]  N. Cohen,et al.  The NEWLEAD program: a new method for the design of candidate structures from pharmacophoric hypotheses. , 1993, Journal of medicinal chemistry.

[19]  I. Kuntz,et al.  Structure-based discovery of inhibitors of thymidylate synthase. , 1993, Science.

[20]  Hans-Joachim Böhm,et al.  The computer program LUDI: A new method for the de novo design of enzyme inhibitors , 1992, J. Comput. Aided Mol. Des..

[21]  F E Cohen,et al.  Structure-based inhibitor design by using protein models for the development of antiparasitic agents. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Richard A. Lewis,et al.  Automated site-directed drug design : the formation of molecular templates in primary structure generation , 1989, Proceedings of the Royal Society of London. B. Biological Sciences.

[23]  I. Kuntz,et al.  Automated docking with grid‐based energy evaluation , 1992 .

[24]  P M Dean,et al.  Automated site-directed drug design: a general algorithm for knowledge acquisition about hydrogen-bonding regions at protein surfaces , 1989, Proceedings of the Royal Society of London. B. Biological Sciences.

[25]  H. Berendsen,et al.  ALGORITHMS FOR MACROMOLECULAR DYNAMICS AND CONSTRAINT DYNAMICS , 1977 .

[26]  A Itai,et al.  Confirmation of usefulness of a structure construction program based on three-dimensional receptor structure for rational lead generation. , 1993, Journal of medicinal chemistry.

[27]  Conrad C. Huang,et al.  Automated site-directed drug design using molecular lattices , 1992 .

[28]  Richard A. Lewis,et al.  Automated site-directed drug design: the concept of spacer skeletons for primary structure generation , 1989, Proceedings of the Royal Society of London. B. Biological Sciences.

[29]  J M Blaney,et al.  A geometric approach to macromolecule-ligand interactions. , 1982, Journal of molecular biology.

[30]  Chris M. W. Ho,et al.  FOUNDATION: A program to retrieve all possible structures containing a user-defined minimum number of matching query elements from three-dimensional databases , 1993, J. Comput. Aided Mol. Des..

[31]  Hans-Joachim Böhm,et al.  LUDI: rule-based automatic design of new substituents for enzyme inhibitor leads , 1992, J. Comput. Aided Mol. Des..

[32]  P. Goodford.  A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[33]  Akiko Itai,et al.  Automatic creation of drug candidate structures based on receptor structure. Starting point for artificial lead generation , 1991 .

[34]  G J Williams,et al.  The Protein Data Bank: a computer-based archival file for macromolecular structures. , 1977, Journal of molecular biology.

[35]  David A. Pearlman,et al.  CONCEPTS: New dynamic algorithm for de novo drug suggestion , 1993, J. Comput. Chem..

[36]  D. Norbeck,et al.  Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. , 1990, Science.

[37]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[38]  Andrew R. Leach,et al.  An investigation into the construction of molecular models by the template joining method , 1988, J. Comput. Aided Mol. Des..

[39]  J Moult,et al.  Docking by least-squares fitting of molecular surface patterns. , 1992, Journal of molecular biology.

[40]  Conrad C. Huang,et al.  The MIDAS display system , 1988 .

[41]  M. Lawrence,et al.  CLIX: A search algorithm for finding novel ligands capable of binding proteins of known three‐dimensional structure , 1992, Proteins.

[42]  W. Kabsch.  A solution for the best rotation to relate two sets of vectors , 1976 .

[43]  Valerie J. Gillet,et al.  SPROUT: A program for structure generation , 1993, J. Comput. Aided Mol. Des..

[44]  R. Wade,et al.  New hydrogen-bond potentials for use in determining energetically favorable binding sites on molecules of known structure. , 1989, Journal of medicinal chemistry.

[45]  Glen Eugene Kellogg,et al.  HINT: A new method of empirical hydrophobic field calculation for CoMFA , 1991, J. Comput. Aided Mol. Des..

[46]  PatrickY.-S. Lam,et al.  Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. , 1994, Science.

[47]  Robert P. Sheridan,et al.  FLOG: A system to select ‘quasi-flexible’ ligands complementary to a receptor of known three-dimensional structure , 1994, J. Comput. Aided Mol. Des..